Physician profile
Peter Ventre
NPI 1659569952
$28,926.77
in general payments reported to CMS, 2019-2025
25 companies · $16K in 2025
The $16K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $28.03 · 2021: $373 · 2022: $320 · 2023: $46.06 · 2024: $125 · 2025: $16K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $15K · Travel and Lodging: $542 · Food and Beverage: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,106.25 |
| Travel and Lodging | $541.91 |
| Food and Beverage | $171.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eli Lilly and Company | $15,648.16 | 2025 | |
| Janssen Pharmaceuticals, INC | $7,383.16 | 2019-2023 | Spravato, Invega Trinza, Invega Sustenna |
| Alkermes, INC. | $5,249.63 | 2019 | |
| Livanova USA, INC. | $133.51 | 2021 | |
| Axsome Therapeutics, INC. | $124.99 | 2024 | Auvelity |
| Corium, LLC | $121.73 | 2022 | |
| Novartis Pharmaceuticals Corporation | $120.18 | 2022 | |
| Abbvie INC. | $73.92 | 2021-2022 | |
| Brainsway USA INC | $17.84 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $15.60 | 2020 | |
| Merck Sharp & Dohme LLC | $14.19 | 2021 | |
| Lundbeck LLC | $12.43 | 2020 | |
| Orexo US, INC. | $11.43 | 2021 |
12 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Ventre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.